Article
09 Apr 2026
U.S. Supreme Court Narrows ISP Liability for Copyright Infringement — What Cox Communications, Inc. v. Sony Music Entertainment Means for Canada
AUTHORS CONTENT
Article
09 Apr 2026
Canada's Dormant DIN Problem: How Marketing Status Is Undermining Pharmaceutical IP Protections Under CUSMA
Article
31 May 2021
Virtual Appellate Advocacy: Zoom Your Way To Success
Article
31 Mar 2020
COVID-19: Canadian Government Can Now Use Patented Inventions To Respond To The Public Health Emergency
Article
26 Dec 2019
The Supreme Court Of Canada Simplifies The Standard Of Review Analysis In Historic Super Bowl Trilogy
Article
03 May 2018
Canadian Government's IP Strategy Seeks To Boost Innovation, Increase IP Literacy, And Rein-In Patent Trolls
Article
12 Sep 2017
Revised NOC Regulations To Come Into Force On September 21, 2017
Article
16 Aug 2017
‘Promise Doctrine' Abolished By The Supreme Court Of Canada
Article
20 Jul 2017
Ten Significant Changes To Canada's NOC Regulations
Article
10 Jul 2017
‘Promise Doctrine' Abolished By The Supreme Court Of Canada
Article
23 Jan 2017
NPEs Beware: Contorted Construction Of A Patent Will Attract Elevated Costs
Article
16 Nov 2016
CETA Implementation In Canada: Bill C-30 Brings Significant Changes To The Canadian Patent System
Article
18 Apr 2016
Largest Patent Infringement Award In Canada Stands: Apotex Denied Leave To Appeal To The SCC
Article
02 Dec 2015
Every Innovative Company Needs An IP Strategy
Article
31 Jul 2015
Canada's Federal Court Of Appeal Upholds C$180 Million Judgment In Favour Of Merck Against Apotex In A Landmark Patent Damages Ruling
Article
09 Jun 2015
Federal Court Of Appeal Clarifies Misunderstanding: Factual Basis And Line Of Reasoning Need Not Be Disclosed In The Patent
Article
01 Oct 2014
Canada And The EU Successfully Conclude CETA: What It Means To The Pharmaceutical Industry
Article
06 Mar 2014
Mccarthy Tétrault Files Brief In U.S. Supreme Court
Article
20 Sep 2013
Ontario Court Of Appeal Upholds Summary Judgment Dismissing Apotex’s Claim For Unjust Enrichment And Disgorgement Of Profits
Article
19 Jul 2013
Merck Awarded More Than $180 Million Against Apotex For Infringement Of Lovastatin Patent